> ## Content Index
> Fetch the complete content index at: https://chinapharmadesk.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# GSK terminates camlipixant China Phase 3 as multinationals and BeOne reset field economics
- URL: https://chinapharmadesk.com/gsk-camlipixant-china-termination-mnc-field-reset/
- Published: 2026-11-21T11:19:49.000Z
- Updated: 2026-11-21T11:19:50.000Z
- Description: GSK formally terminated its 75-patient China Phase 3 extension for camlipixant (BLU-5937, NCT07650084) on Nov 20, 2026 as GSK, Bayer, Pfizer, and BeOne (06160.HK) restructured China sales hierarchies.
- Author: Lin Yi
- Tags: Desk analysis, Pipeline, Capital, Market Access

On November 20, 2026, [GlaxoSmithKline (LSE/NYSE: GSK) formally updated ClinicalTrials.gov (NCT07650084)](https://clinicaltrials.gov/study/NCT07650084?ref=chinapharmadesk.com) to mark its 24-week China Phase 3 extension study of selective `P2X3` receptor antagonist `camlipixant` (`BLU-5937`) in refractory chronic cough (`RCC`) as **`TERMINATED`** after enrolling **75 participants** across `25 mg BID`, `50 mg BID`, and placebo arms. The registry closure completes the China clinical wind-down of the centerpiece asset from GSK’s `$2.0 billion` (`C$2.7 billion`) acquisition of Bellus Health following the July 17, 2026 [global CALM-2 (NCT05600777, n=1,019) Week 24 primary-endpoint miss](https://www.sec.gov/Archives/edgar/data/1131399/000165495426006705/a8188m.htm?ref=chinapharmadesk.com), leaving only the Phase 2b `BALANCE` trial ([NCT07519395](https://clinicaltrials.gov/study/NCT07519395?ref=chinapharmadesk.com)) in irritable bowel syndrome (`IBS-D` and `IBS-M`) active.

On the exact same day, domestic industry disclosures confirmed that GSK China is cutting roughly **half of its HIV commercial team** after generic entry eroded margins on its oral two-drug regimen `Dovato` (`dolutegravir/lamivudine`) before long-acting injectable `Cabenuva` (`cabotegravir + rilpivirine`) could reach scale—part of a synchronized November 2026 reorganization across Bayer, Pfizer, Gilead, and [BeOne Medicines (HKEX: 06160; SSE: 688235; NASDAQ: ONC)](https://chinapharmadesk.com/china-dual-commercial-drug-lists-nhsa-iac/) that is stripping middle-management layers and dismantling standalone county-hospital (`xianyu`) sales forces across China.

## Why camlipixant’s China extension closed—and what remains of the P2X3 class

When GSK initiated the quadruple-masked `CALM-2 China Extension` (`NCT07650084`) on November 21, 2025, `camlipixant` (`BLU-5937`) was positioned as a high-selectivity `P2X3` antagonist engineered to avoid the 60%+ rates of dysgeusia (taste disturbance) that led the U.S. FDA to issue two Complete Response Letters to Merck’s (`NYSE: MRK`) first-generation `P2X3`/`P2X2/3` antagonist `gefapixant` (`Lyfnua`, approved in Japan, the EU, and China).

However, the aggregate readout from GSK’s two global Phase 3 trials (`CALM-1` \[`NCT05599191`, 52 weeks\] and `CALM-2` \[`NCT05600777`, 24 weeks, `n=1,019`\]) exposed a narrow therapeutic window:

- **Dose-dependent and time-point fragility**: While `camlipixant` `50 mg BID` achieved a statistically significant reduction in 24-hour ambulatory cough frequency versus placebo at **Week 12** in `CALM-1`, the identical `50 mg BID` dose **failed to reach statistical significance at Week 24** in `CALM-2`.
- **Lower dose and patient-reported outcome failures**: The `25 mg BID` arm failed to reach statistical significance in either `CALM-1` or `CALM-2`, and neither dose met prespecified thresholds on key secondary endpoints including the patient-reported **Chronic Cough Diary (`CCD`)**.
- **China operational consequence (`NCT07650084`)**: Although `NCT07650084` tracked specific `P2X3` adverse events of medical interest—taste disturbance, oral hypoesthesia, oral paresthesia, and corneal findings—GSK halted the trial at **75 enrolled patients** after concluding on July 17 that the limited aggregate efficacy would not transform `RCC` care.

## Multinationals and BeOne recalculate China field-force and county-market unit economics

Alongside pipeline pruning in respiratory medicine, November 20 disclosures detailed how multinational pharmaceutical companies (`MNCs`) and leading domestic biotechs are restructuring their China commercial organizations heading into the 2027 budget cycle. Unlike earlier waves of layoffs driven purely by [Volume-Based Procurement (VBP)](https://chinapharmadesk.com/china-pharma-glossary/) price cliffs on off-patent blockbusters, the late-2026 adjustments target **organizational hierarchy compression** and **low-margin county-market (`xianyu`) teams**:

| Company (Ticker)                                             | November 2026 China Commercial Restructuring Action                                                                                                                                                                 | Underlying Portfolio & Unit-Economics Driver                                                                                                                                                                                                   |
| ------------------------------------------------------------ | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| **GSK (LSE/NYSE: GSK)**                                      | **Cuts \~50% of China HIV commercial team** alongside NCT07650084 (camlipixant RCC) termination                                                                                                                     | Domestic first-generic launch against oral two-drug regimen Dovato (dolutegravir/lamivudine) compressed margins before long-acting injectable Cabenuva (cabotegravir/rilpivirine) scaled                                                       |
| **Bayer (ETR: BAYN)**                                        | Rolls out **AGM (Area General Manager) model** in China general medicine; **eliminates Regional Sales Manager (RSM) tier**, compressing hierarchy from **12 layers to 7–8 layers**                                  | Flattens mature primary-care overhead under tightened Medical Representative Management Measures compliance rules                                                                                                                              |
| **Pfizer (NYSE: PFE)**                                       | **Dissolves standalone Broad Market (Guangkuo Shichang / county) unit**, merging county coverage back into vertical therapeutic Business Units (BUs)                                                                | Eliminates duplicate regional management infrastructure separating core urban and county hospital tiers                                                                                                                                        |
| **Gilead Sciences (NASDAQ: GILD)**                           | Trims commercial headcount across **mature liver disease, anti-infective, and legacy oncology** franchises                                                                                                          | Reallocates China operating budget toward local clinical R&D, medical affairs, and market access                                                                                                                                               |
| **BeOne Medicines (06160.HK / 688235.SS / ONC)**             | **Dismantles standalone County Market (Xianyu) unit**; shifts on Nov 20 to **“Core BU + CSO”** dual-track model (high-potential county hospitals folded into core oncology BUs; lower-tier counties handed to CSOs) | Avoids carrying fixed internal sales overhead in low-yield grassroots oncology territories while keeping top county cancer centers in-house                                                                                                    |
| **Novartis (SIX: NOVN)** *(County benchmark)*                | Previously consolidated county operations after county team spent **\>RMB 300 million in annual operating costs** to generate **RMB 420 million in 2024 revenue** (**<15% gross margin**)                           | Illustrates why standalone MNC county structures struggle: MNC share in township health centers sits at just **6.5% (\-6% YoY)**                                                                                                               |
| **Jiangsu Hengrui (600276.SS / 01276.HK)** *(Counter-trend)* | **Continues expanding dedicated in-house grassroots/county sales force**                                                                                                                                            | Broad basket of high-volume generics, surgical anesthetics, contrast media, and newly reimbursed [Class 1](https://chinapharmadesk.com/china-pharma-glossary/) drugs amortizes per-rep fixed costs across multiple county hospital departments |

## Why the 780-million-person county market failed the innovation ROI test

During the late 2010s, multinationals and domestic oncology biotechs built dedicated county-market divisions to chase China’s 780 million county and rural residents across roughly one million grassroots medical institutions. Operating data from 2024–2026 explain why both `MNCs` (Pfizer, Novartis, AstraZeneca) and domestic oncology leaders (`BeOne`) are now dismantling standalone county hierarchies:

1. **Volume grows, but revenue skews to low-priced chronic generics**: While prescription volume at grassroots and county institutions grows faster than urban tertiary hospitals, grassroots channels represent only **24% of China’s total pharmaceutical market value**. In township health centers (`xiangzhen weishengyuan`), domestic companies occupy all top 20 spots, multinational market share has fallen to **6.5%** (`-6% YoY`), and innovative oncology share has turned negative.
2. **Diagnostic and physician-credential bottlenecks block complex therapies**: As of year-end 2024, fewer than **50%** of rural doctors (`xiangcun yisheng`) held full licensed physician or assistant licensed physician (`zhiye/zhuli yishi`) credentials. Without pathology immunohistochemistry (`IHC`), next-generation sequencing (`NGS`), or adverse-event management infrastructure for immune-related toxicities, complex oncology and autoimmune biologics cannot be safely initiated at most lower-tier county facilities.
3. **Sub-15% gross margins destroy standalone team economics**: As Novartis’s disclosed county P&L (`>RMB 300 million` annual team cost against `RMB 420 million` in 2024 sales, yielding a **`<15%` gross margin**) demonstrated, maintaining a separate management pyramid for county hospitals erodes group operating margins. Even when [four-ministry Notice No. 18 pushes tight-knit medical alliances (jinmixing yilianti)](https://chinapharmadesk.com/china-class1-hospital-formulary-policy/) to synchronize Class 1 drug formularies down to county member hospitals, prescription initiation remains concentrated in the top 300 to 500 high-volume county general hospitals—which BeOne and Pfizer can cover directly through their core vertical oncology BUs while outsourcing the long tail to regional contract sales organizations (`CSOs`).

## What to watch next

1. **ClinicalTrials.gov `NCT07519395` (`BALANCE` Phase 2b)**: Whether `camlipixant` demonstrates visceral analgesic efficacy in `IBS-D` and `IBS-M` after GSK’s complete exit from `RCC` (`NCT05599191`, `NCT05600777`, `NCT07650084`).
2. **FY2026 selling-expense ratios at BeOne (`06160.HK`) versus Hengrui (`600276.SS`)**: How BeOne’s transition to the “Core BU + `CSO`” county model affects its Q4 2026 and 1H 2027 China SG&A-to-revenue ratio as [newly added 2026 NRDL indications](https://chinapharmadesk.com/china-2026-nrdl-commercial-list-bridge/) take effect on January 1, 2027.